Anika Therapeutics (ANIK) Cash from Operations Growth (3y) (2014 - 2026)
Anika Therapeutics (ANIK) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn | 27.85% |
| 10 | Anika Therapeutics | 203.37 Mn | 136.58 Mn | 19.00 Mn | -10.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.23% |
| Dec 31, 2025 | 112.83% |
| Sep 30, 2025 | 36.37% |
| Jun 30, 2025 | -27.26% |
| Mar 31, 2025 | 58.87% |
| Dec 31, 2024 | -29.28% |
| Sep 30, 2024 | 34.49% |
| Jun 30, 2024 | -31.02% |
| Mar 31, 2024 | 62.72% |
| Dec 31, 2023 | 12.04% |
| Sep 30, 2023 | 3.41% |
| Jun 30, 2023 | -62.92% |
| Mar 31, 2023 | -76.11% |
| Dec 31, 2022 | -66.70% |
| Sep 30, 2022 | -35.40% |
| Jun 30, 2022 | -17.35% |
| Mar 31, 2022 | -30.47% |
| Dec 31, 2021 | -23.56% |
| Sep 30, 2021 | -42.49% |
| Jun 30, 2021 | -1.34% |